SIC
FULC icon

SJS Investment Consulting’s Fulcrum Therapeutics FULC Stock Holding History

SJS Investment Consulting’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275 Sell
75
-1
-1% -$6 ﹤0.01% 2415
2026
Q1 		$583 Buy
76
+73
+2,433% +$677 ﹤0.01% 1672
2025
Q4 		$34 Buy
+3
New +$31 ﹤0.01% 2046

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SJS Investment Consulting's FULC Position: Q2 2026 in Review

SJS Investment Consulting reduced its Fulcrum Therapeutics (FULC) stake by 1.3% in Q2 2026, selling an estimated $6 and leaving 75 shares worth $275. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

SJS Investment Consulting first reported a position in FULC in Q4 2025 and has held it in 3 quarters since. The position peaked at $583 in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • SJS Investment Consulting held 75 shares of Fulcrum Therapeutics worth $275 as of Q2 2026.
  • SJS Investment Consulting sold 1 Fulcrum Therapeutics share in Q2 2026, an estimated $6.
  • Fulcrum Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2415 holding.
  • SJS Investment Consulting first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • SJS Investment Consulting's Fulcrum Therapeutics position peaked at $583 in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.